Medicenna Therapeutics Corp. (MDNA) Stock Analysis

What Medicenna Therapeutics Corp. does

Medicenna Therapeutics Corp. is an immunotherapy company dedicated to discovering and commercializing innovative Superkines and "empowered Superkines" for the treatment of various cancers and other ailments. The company's primary therapeutic candidate, MDNA55 (an interleukin-4 (IL-4) EC), has successfully completed a Phase IIb clinical trial for recurrent glioblastoma. This product is also in earlier preclinical and clinical development stages for other brain and non-brain tumors. Medicenna's pipeline also features several other promising compounds: MDNA11: An enhanced version of IL-2, engineered to activate and proliferate the immune cells essential for fighting cancer. MDNA209: An IL-2 antagonist aimed at treating autoimmune conditions such as multiple sclerosis and graft-versus-host disease. MDNA413: A dual IL-4/IL-13 antagonist being developed for cancer immunotherapies. MDNA132: An IL-13 Superkine currently in development for solid tumors. Additionally, the company utilizes its proprietary BiSKITs platform, an advanced technology designed to create custom Superkines by fusing them with other proteins, antibodies, cytokines, or Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

Key metrics

ETFs linked to MDNA

Broad-market and Healthcare sector ETFs an investor holding Medicenna Therapeutics Corp. is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how MDNA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Medicenna Therapeutics Corp.?

Medicenna Therapeutics Corp. trades under the ticker MDNA on NASDAQ.

Which exchange is MDNA listed on?

MDNA is listed on NASDAQ.

What sector does Medicenna Therapeutics Corp. operate in?

Medicenna Therapeutics Corp. is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze MDNA in a portfolio?

PortView shows MDNA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.